

# A leading capability in the development of biomaterials functionalised with biological signalling molecules for blood vessel repair and regeneration, for therapeutic application.

### Competitive advantage

Fundamental and multidisciplinary expertise in:

- Synthetic and natural biomaterials
- Blood vessel cell surface and extracellular matrix molecules
- Recombinant protein expression
- Biochemical, biophysical and cell-based functional assays
- In vivo models

#### **Impact**

 Developing next generation biomaterials that interface with the body to direct blood vessel and tissue repair

#### Successful outcomes

- IP portfolio in methods to produce signalling molecules
- Preclinical testing for novel vascular graft coating
- · Preclinical testing for diabetic wound healing
- Coatings for prolonged platelet storage

# Capabilities and facilities

• State-of-the-art preclinical biomaterial and biological molecule development and testing laboratories encompassing in vitro and in vivo analyses

## Our partners

- Synedgen Inc
- TriCol Biomedical
- Diabetes Australia
- Australian Red Cross Blood Service

### More Information

Associate Professor Megan Lord

Graduate School of Biomedical Engineering

T: +61 2 9385 3910 E: m.lord@unsw.edu.au

UNSW Knowledge Exchange knowledge.exchange@unsw.edu.au www.capabilities.unsw.edu.au +61(2) 9385 5008